Skip to main content
. 2012 Aug 31;11(11):1457–1467. doi: 10.1074/mcp.M112.019232

Fig. 5.

Fig. 5.

MS-identified HLA-DR7-restricted peptides from MCF10/DR7/CD80 vaccine cells activate tumor-specific PBMC from HLA-DR7+ healthy donors and breast cancer patients. A, PBMC activation scheme: HLA-DR7+ PBMC were primed with peptide for 6 days, expanded with IL-15 for 7 days, rested for 24 h, boosted for 48 h with Ii− (MCF10/DR7/CD80) or Ii+ (MCF10/DR7/CD80/Ii) cells, and IFNγ production measured by ELISA. B, PBMC were primed with Her2 p776 and either peptide 46 (healthy donor PBMC BC100206) or peptide 43 (healthy donor PBMC BC100306), and boosted with the indicated cells shown on the x axis. C, Peptide-activated PBMC do not react with nonmalignant breast tissue cells. PBMC from healthy donor BC061005 were primed with either peptide 46 or 43 and boosted with MCF10/DR7/CD80 or nonmalignant HLA-DR+ MCF10A cells. D, MS-identified peptides activate breast cancer patients' PBMC. HLA-DR7+ PBMC from healthy donor BC051005 and breast cancer patient 3 (left panel) were primed with peptide 48 (left panel) or healthy donor BC061005 and breast cancer patient 10 were primed with peptide 43 (right panel) and boosted with MCF10/DR7/CD80 or nonmalignant MCF10A cells.